Suppr超能文献

肝硬化患者在等待肝移植时的虚弱和肌肉减少症:一项单中心前瞻性队列研究的证据。

Frailty and sarcopenia in patients with cirrhosis awaiting liver transplantation: evidence from a single-centre, prospective cohort study.

机构信息

Multivisceral Transplant Unit, Gastroenterology, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Via Giustiniani 2, 35128, Padua, PD, Italy.

Hepato-Biliary-Pancreatic and Liver Transplant Unit, Padua University Hospital, Padua, Italy.

出版信息

Updates Surg. 2024 Sep;76(5):1807-1818. doi: 10.1007/s13304-024-01962-9. Epub 2024 Aug 5.

Abstract

Sarcopenia and frailty are common complications in patients with cirrhosis evaluated for liver transplantation (LT). Although the negative impact of sarcopenia on patient's outcome has been well studied, the prognostic role of frailty is not as clear. We assessed the prevalence of sarcopenia and frailty and the clinical impact of frailty in a prospective cohort of cirrhosis patients with and without hepatocellular carcinoma (HCC) listed for LT. Patients with cirrhosis were prospectively recruited at the time of admission into the waiting list. Clinical and lab values were collected. Physical frailty was assessed by liver frailty index (LFI) and patients were categorized into robust (< 3.2); pre-frail (between 3.2 and 4.5), and frail (> 4.5). Skeletal muscle mass was evaluated via skeletal muscle index (SMI) obtained from last CT scan before LT; sarcopenia was defined by SMI < 50 cm/m in males and < 39 cm/m in females. 105 patients were included, of which 42 (40%) had hepatocellular carcinoma (HCC). In patients without HCC (63.5% males, median age 61 years), 36.5% were frail, 50.8% were pre-frail and 12.7% were robust. Frail patients were older than non-frail patients (63 vs. 56; p = 0.008) and had more severe liver disease (Child C: 65% vs. 37.5%; p = 0.02). Prevalence of sarcopenia in patients without HCC was 63%, with similar value of median SMI between frail and not frail patients (p = 0.454). Patients with HCC (78.6% males, 65 years old) were 21.4% frail, 61.9% pre-frail, and 16.7% robust. Frail patients had more severe liver disease (Child C: 77% vs. 18.2%; p = 0.004), whereas age was comparable to non-frail patients; among patients without HCC, during a median follow-up of 263 days, 17% died (of which 72% were frail) and 10 patients were delisted due to clinical improvement (none of whom were frail). Among those with HCC, during a median follow-up of 289 days, 4 (9%) patients died of which 50% were frail. Frailty and sarcopenia are common complications in patients with cirrhosis awaiting LT. Frailty appears to be associated with an increased risk of mortality during wait-list time especially in those with decompensated cirrhosis. At univariate analysis Meld score, Child score and presence of frailty were found to be associated with shorter survival, however, at multivariate analysis presence of frailty and Child C vs. A/B were the only independent predictor of death. Larger cohorts are required to confirm these results.

摘要

肌肉减少症和衰弱是接受肝移植 (LT) 评估的肝硬化患者的常见并发症。虽然肌肉减少症对患者预后的负面影响已得到充分研究,但衰弱的预后作用尚不清楚。我们评估了前瞻性队列中伴有和不伴有肝细胞癌 (HCC) 的肝硬化患者的肌肉减少症和衰弱的患病率,以及衰弱的临床影响。在进入等待名单时,前瞻性地招募了患有肝硬化的患者。收集了临床和实验室值。通过肝脏衰弱指数 (LFI) 评估身体衰弱情况,并将患者分为强壮(<3.2);虚弱前期(3.2 至 4.5)和虚弱(>4.5)。通过 LT 前最后一次 CT 扫描获得的骨骼肌指数 (SMI) 评估骨骼肌量;SMI<50cm/m 为男性,<39cm/m 为女性时定义为肌肉减少症。共纳入 105 例患者,其中 42 例(40%)患有肝细胞癌 (HCC)。在无 HCC 的患者中(63.5%为男性,中位年龄 61 岁),36.5%为虚弱,50.8%为虚弱前期,12.7%为强壮。虚弱患者比非虚弱患者年龄更大(63 岁比 56 岁;p=0.008),肝脏疾病更严重(Child C:65%比 37.5%;p=0.02)。无 HCC 患者肌肉减少症的患病率为 63%,虚弱患者和非虚弱患者的中位 SMI 值相似(p=0.454)。患有 HCC(78.6%为男性,65 岁)的患者中,21.4%为虚弱,61.9%为虚弱前期,16.7%为强壮。虚弱患者的肝脏疾病更严重(Child C:77%比 18.2%;p=0.004),而年龄与非虚弱患者相当;在无 HCC 的患者中,中位随访 263 天期间,17%死亡(其中 72%为虚弱),10 名患者因临床改善而被除名(无一人为虚弱)。在患有 HCC 的患者中,中位随访 289 天期间,4 名(9%)患者死亡,其中 50%为虚弱。肌肉减少症和衰弱是等待 LT 的肝硬化患者的常见并发症。虚弱似乎与等待名单期间的死亡率增加有关,尤其是在失代偿性肝硬化患者中。在单变量分析中,MELD 评分、Child 评分和虚弱的存在与生存率降低相关,但在多变量分析中,虚弱和 Child C 与 A/B 是死亡的唯一独立预测因素。需要更大的队列来证实这些结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验